Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:50619 |
Name | paranasal sinus cancer |
Definition | A respiratory system cancer that is located_in the paranasal sinuses. |
Source | DiseaseOntology.org |
Alt Ids | DOID:2442 DOID:2767 DOID:4689 DOID:1354 DOID:2765 |
Path | disease disease of cellular proliferation cancer organ system cancer respiratory system cancer paranasal sinus cancer |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01540682 | Phase I | Alisertib + Cetuximab | MLN8237 in Head and Neck Cancer | Completed | USA | 0 |
NCT02196168 | Phase II | Adavosertib Cisplatin | Cisplatin With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent or Metastatic Head and Neck Cancer | Terminated | CAN | 0 |
NCT02538510 | Phase Ib/II | Pembrolizumab + Vorinostat | Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer and Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery | Completed | USA | 0 |
NCT02567422 | Phase I | Berzosertib + Cisplatin | VX-970, Cisplatin, and Radiation Therapy in Treating Patients With Locally Advanced HPV-Negative Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT02795156 | Phase II | Cabozantinib Afatinib Regorafenib | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | Completed | USA | 0 |
NCT02834013 | Phase 0 | Ipilimumab + Nivolumab | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | Active, not recruiting | USA | 1 |
NCT02994069 | Phase II | Cisplatin | Cisplatin + Radiation in SCCHN and Correlation With Oxidative Stress Markers | Active, not recruiting | USA | 0 |
NCT03238365 | Phase I | Nivolumab + Tadalafil Nivolumab | Nivolumab With or Without Tadalafil in Treating Patients With Recurrent Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery | Completed | USA | 0 |
NCT03370276 | Phase Ib/II | Cetuximab + Nivolumab | Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03381183 | Phase Ib/II | Cyclophosphamide + Durvalumab + Tremelimumab | IRX-2 Regimen, Durvalumab, Tremelimumab for Incurable Head and Neck Squamous Cell Carcinoma | Active, not recruiting | USA | 0 |
NCT03422536 | Phase II | Ficlatuzumab Cetuximab + Ficlatuzumab | Ficlatuzumab With or Without Cetuximab in Treating Patients With Cetuximab-Resistant, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | Completed | USA | 0 |
NCT03539198 | Phase 0 | Nivolumab | Study of Proton SBRT and Immunotherapy for Recurrent/Progressive Locoregional or Metastatic Head and Neck Cancer | Terminated | USA | 0 |
NCT03719690 | Phase II | Tipifarnib | Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy (AIM-HN/SEQ-HN) | Completed | USA | NOR | NLD | ITA | GRC | GBR | ESP | DNK | DEU | BEL | AUT | AUS | 4 |
NCT04290546 | Phase I | CIML-NK cells + Ipilimumab + Nogapendekin alfa inbakicept CIML-NK cells + Nogapendekin alfa inbakicept | CIML NK Cell in Head & Neck Cancer | Active, not recruiting | USA | 0 |
NCT04722523 | Phase I | Cemiplimab + Cetuximab + Cisplatin + Docetaxel Carboplatin + Cemiplimab + Cetuximab + Docetaxel | A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer | Recruiting | USA | 0 |
NCT05027633 | Phase II | Cisplatin + Docetaxel + Pembrolizumab Carboplatin + Docetaxel + Pembrolizumab | Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA) | Recruiting | USA | 0 |
NCT05057247 | Phase II | Docetaxel + Duvelisib | Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC | Active, not recruiting | USA | 0 |
NCT05172245 | Phase I | Cisplatin + Ipatasertib | Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | Recruiting | USA | CAN | 0 |
NCT06005324 | Phase I | Cisplatin Cisplatin + Fluorouracil + Hydroxyurea Carboplatin + Cetuximab + Paclitaxel | Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer | Recruiting | USA | 0 |
NCT06110195 | Phase I | Carboplatin + Paclitaxel + Xevinapant | Study of Xevinapant With Radiation and Chemotherapy for Patients With Head and Neck Cancer | Active, not recruiting | USA | 0 |
NCT06176989 | Phase II | Enasidenib | Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors | Recruiting | USA | 0 |
NCT06239220 | Phase II | Cetuximab + Nogapendekin alfa inbakicept + PD-L1.t-haNK cells | PD-L1 t-haNK, N-803 IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC | Recruiting | USA | 0 |
NCT06636734 | Phase II | Lovastatin + Pembrolizumab | Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial | Not yet recruiting | USA | 0 |
NCT06648096 | Phase Ib/II | Afatinib | Afatinib in Patients with Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) (AFAN) | Not yet recruiting | ESP | DEU | 0 |